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Drug addiction is a heritable disease characterized by compulsive drug use. The biological 
mechanisms driving addiction remain largely unknown.1 Previous studies show shared genetic 
mechanisms underlying addiction risk phenotypes such as anxiety, depression, and 
novelty/sensation seeking.2,3 Therefore, high-throughput behavioral screening of these traits in 
single gene knockout mice can allow for the rapid detection of addiction risk candidate genes and 
mechanisms. Many of these traits are represented in the Knock-Out Mouse Program (KOMP) 
phenotyping pipeline. Of the initial two hundred twenty-one strains screened in this program, we 
tested nineteen phenodeviant knock-out mouse strains with C57BL/6NJ controls (N = 951) for 
effects on drug consumption and preference using a two-bottle choice paradigm with either ethanol 
(EtOH), methamphetamine (MA), or nicotine. Initial screening confirmed that fifteen of the 
nineteen gene deletions significantly affected EtOH consumption or preference (EtOH-related 
traits), MA consumption or preference (MA-related traits), or both. Thirteen strains exhibited drug 
specific effects and two exhibited significantly altered patterns of consumption, preference, or both 
for MA and EtOH. To investigate the shared relationships underlying drug consumption and 
predisposing drug-naïve phenotypes, we ran a principle component analysis. This revealed a 
 
 
complex relationship among predisposing behaviors and their effects on drug-related phenotypes 
across different strains, instead of consistent predictive relationships between predisposing 
behaviors and drug consumption phenotypes. Using a multivariate strategy, a second screening 
approach was performed based on multidimensional phenodeviance across predisposing traits. In 
this analysis, based on four hundred two inbred strains, fifteen KOMP lines chosen based on 
phenodeviance, in addition to six expert nominated strains, and were assessed with controls 
(N=608) using both methamphetamine two- bottle choice and ethanol drinking-in-the-dark 
paradigms. Results from second screening revealed ten more genes affecting drug phenotypes, 
three of which altered both methamphetamine and ethanol related traits. This shows that using a 
multidimensional assessment of predisposing traits enriched our candidate genes with a higher rate 
of effects across multiple drugs. Collectively this project provided twenty-five new confirmed gene 
deletion mutants with addiction risk effects, representing multiple distinct, novel biological 
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Addiction is a complex brain disease that manifests both behaviorally as well as 
physiologically.4,5 Addiction is characterized as the compulsive seeking of rewarding stimulation 
despite reduction in euphoric effects and other negative consequences that may accompany this 
compulsive seeking for the individual.4–7 While addiction is not a disease that is part of the 
Diagnostic and Statistical Manual, version 5 (DSM-5), many of the defining traits associated with 
addiction are covered by the diagnostic criteria for Substance Use Disorders (SUD). Addiction is 
often used in correspondence with severe SUDs, but making a precise diagnosis of the severity of 
an SUD can be difficult even with the clearly defined diagnostic criteria set forth by the (DSM-5). 
The difficulty establishing a precise diagnosis is that diagnostic criteria are based on symptom 
counts, and it has been shown that while two individuals may check off the same number of 
diagnostic criteria for an SUD they can drastically differ on the severity of their addiction 
depending on which criteria they endorse.8 With the numerous biological and societal factors that 
go into each individual case of addiction or SUD, studying their basic underlying features of these 
diseases is critical to improve our understanding of them. 
With increased prevalence of mental health issues and drug availability SUDs are highly 
prevalent diseases that cause devastating effects to both the individual and society. In 2018, the 
Substance Abuse and Mental Health Services Administration (SAMHSA) conducted a national 
survey that estimated 164.8 million (60.2%) Americans had used alcohol, nicotine, or illicit drugs 
within the past month, and 20.3 million people ages twelve and up are currently suffering from an 
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SUD related to their use of alcohol or illicit drugs.9 The National Institute on Drug Abuse (NIDA) 
estimated that this use of drugs and alcohol costs Americans more than $700 billion and contributes 
to 570,000 deaths per year. 4,10 Collectively, these data illustrate that as a result of increased access 
to drugs and alcohol SUDs are becoming drastically more prevalent diseases with devastating 
effects on the individual and society.  
1.2. Neurocircuitry of Addiction  
 
Repeated exposure to drugs of abuse, used by people with SUDs, lead to compulsive 
behavior through their pharmacological effects on dopaminergic neurons in the reward pathway 
common to all mammals.5 The regions of the brain most commonly associated with addiction and 
SUDs are the prefrontal cortex (PFC), extended amygdala, and the ventral and dorsal striatum, 
which include components of the mesolimbic pathway (reward pathway). Due to evolutionary 
importance these reward pathways have been highly conserved across many different species12–14. 
These pathways likely evolved to increase Darwinian fitness through incentive salience 
(motivation) and hedonic pleasure (liking), but because drugs of abuse activate habit formation 
pathways, the motivation for drugs can persist even after the liking subsides. 5,7,15 
 The NAc is an ancient forebrain structure which may have originally developed to increase 
Darwinian fitness through incentive salience for rewarding stimuli such as food and sex.15 Today 
highly refined drugs of abuse hijack this system with over stimulation of dopaminergic neurons 
falsely signifying large benefits to our survival.15 The excessive release of dopamine from the 
terminals of VTA neurons within the NAC leads to motivational arousal in the individual that 
creates a drive to procure the drug again. Along with innervating the NAc, the VTA also innervates 
regions of the PFC that in conjunction with the amygdala make environmental and emotional cues 
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respectively to guide further decision about the motivation to procure the drug.5,16 As drug use 
continues, these cues and associations get stronger and incentive salience for the drugs continues 
to escalate as more cues become associated with their use. In addition to the increasing motivation 
for drug use, dopamine neurons in the substantia nigra (SN) translate the recurring reward signals 
into habitual actions that become increasingly insensitive to the reduction of hedonic response to 
continued drug use and instead use the reinforcement associated with prior experiences17,18. Often 
at this point the euphoric feelings that originally were associated with drug use have subsided and 
further administration of drugs merely reduces the depressive feelings caused by changes to normal 
dopamine levels in the reward pathway so the individual can return to an emotional and 
physiological baseline 7,15. This dysregulation of the reduced hedonic response in the NAc and 
increased incentive salience, driven by positively reinforcing cues stored in the PFC and amygdala, 
can lead to emergence of the compulsive drug taking habits which underlie addiction and 
SUDS.5,7,11,12,17 With the multitude of neural processes and brain regions working in unison there 
are many mechanisms by which genetic and biological variations can alter their function. The 
slight alterations to different brain regions and neural processes can manifest themselves in many 
different behavioral and physiological manners leading to many mechanisms of addiction 
vulnerability in different people. 
1.3. SUDs Comorbidity with Mental Health Disorders 
 
Results from the 2018 Substance Abuse and Mental Health Service Administration 
(SAMHSA) survey show a high rate of comorbidity between SUDs and people that suffer from 
mental illness.9 This study estimated that currently 9.2 million people are suffering from both 
mental illness and an SUD. This estimate represents about twenty percent of all people suffering 
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from mental illnesses.9 The high rates of comorbidity between mental illness and SUDs are 
indicative of potential genetic, neurobiological, and behavioral traits underlying both of these 
complex diseases. Some believe these diseases are connected through the self-medication 
hypothesis, which posits that people take drugs as negative reinforcers that relieve symptoms of 
mental illness. However, self-administration of drugs also alters natural levels of neurotransmitters 
such as dopamine or GABA19,20 in regions of the brain, leading to or exacerbating mental health 
problems. Although the interplay of the disorders and trajectory between 21,22 are not fully 
elucidated, it is clear that SUDs and mental health disorders are two strongly intertwined diseases. 
Using the connections between SUDs and many mental illnesses, studies have shown that many 
predisposing drug-naïve behaviors, personality traits, and co-occurring psychological conditions 
connected to mood disorders such as anxiety, depression, impulsivity, and sensation/novelty 
seeking are associated with the risk for and are also consequences of many aspects of SUDs. 23–26 
These connections between SUDs and mental illnesses can make it a vicious cycle of one disease 
predisposing individuals to the other disease leading to a vicious cycle that is hard to break. 
Although these traits and behaviors may be putting individuals at greater risk, many other factors 
must be taken into account when determining the overall risk of an individual developing an SUD. 
These factors may include socioeconomic status, family/ peer structure, age, sex, genetic 
vulnerability, and other extrinsic influences.1,27,28 Finding the genetic and biological factors that 
underlie substance use and many of the traits associated with mental illness2,3 can provide 




1.4. Role of Genetics in Addiction  
 
Many factors play a role in determining whether an individual will develop an SUD and 
become addicted to that substance. An individual who lives in an environment where there is no 
access to drugs is highly unlikely to develop an addiction to a drug, but few such places exist. 
Beyond environmental access to drugs and predisposing behaviors associated with drug use, not 
all individuals who initiate drug use become addicted to the substances they use implying that 
there must be some underlying biological or genetic vulnerability to addiction. Many studies in 
humans have shown that on average the heritability of substance addiction is around 50% 12,27,29,30 
with hallucinogen use being the least heritable 39% and cocaine use being the most heritable 72% 
according to data from twin studies.1  
Although genetic vulnerability to addiction and substance use is relatively high across 
many substances it can be challenging to identify and examine the effects of any particular 
candidate gene. Due to their highly heterogeneous nature and numerous confounding gene × 
environment interactions, it is therefore a daunting task to identify genes that underlie the 
vulnerability to SUDs and addictions. Historically, researchers have undertaken complex 
hypothesis driven studies to examine the role of a particular gene in often a specific substance use 
paradigm, leading to long, expensive studies that slowly advance our knowledge of the genetic 
factors playing a role in addiction based on already well-studied mechanisms. Much focus has 
gone into studying genetic components underlying substance-specific effects because these genetic 
components can play crucial roles in development of treatments for drug-specific SUDs. In 
addition to studying these substance-specific gene additional focus is being put on identifying and 
characterizing substance-non-specific genes which may underlie generalized substance use. These 
genes that affect use of multiple substances are important as well because they could play a role in 
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developing more generalized substance-use treatments.31 Additionally, it has been shown that 
genes predisposing for addiction risk traits like high intake or preference drinking differ from the 
genes involved in transition from substance use to addiction.32 Distinguishing the genetic factors 
that underlie addiction risk factors like high initial intake from those that underlie susceptibility to 
transition into addiction is a challenging task further slowing the pace for discovery. 
 In contrast, discovery approaches including Genome Wide Association Studies (GWAS) 
allow for the discovery of previously unknown genes in addiction. While GWA studies do not 
have the precise control over factors such as environment and experimental conditions, these 
studies can work directly with vast quantities of human data and therefore, genetic candidates are 
known to be involved in human disease, in contrast to findings from animal models, which need 
to be evaluated from a comparative perspective. Now, using the mass amount of data compiled in 
the human, GWAS researchers can use results from addiction phenotypes and biomarkers to 
identify genetic loci, individual genes, and sometimes even single nucleotide polymorphisms 
(SNPs) that can explain some of the heritability for addiction. 27,28 While GWAS are a promising 
start, data from hundreds of thousands to millions of individuals is required to explore the genetics 
underlying addiction in humans, making the studies of many drugs and many populations cost-
prohibitive.  
Many of the factors that limit genetic discovery in human studies, including environmental 
factors, genetic background, medical history, and sample size are easily controlled when using 
animal models. The use of animal models, such as mice, can serve as a powerful research tool for 
studying many of the genetic and biological mechanisms underlying complex disease 
phenotypes.33–35 Animal models, in combination with advancing genetic engineering technologies, 
have been used to evaluate and characterize hypothesized gene disease associations from human 
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studies and provide therapeutic targets through the use of behavioral assays proven to have 
translational applications.35 Additionally, advancing high-diversity mouse populations such as the 
Diversity Outbred (DO) and Collaborative Cross (CC) stocks greatly increase the power to identify 
genetic factors and biological mechanisms underlying complex diseases when used in a systems 
genetics approach.33 Using these ever advancing animal models and technologies also allow for 
the discovery of high order interactions such as gene × sex intaractions34 and gene × environment 
interactions36 which most human studies are underpowered to detect. Undoubtedly, 
complementary findings from both human and animal models will be required to identify and 
characterize genetic risk factors underlying our susceptibility to addictions and SUDs.  
1.5. Current Treatments and Potential for Pharmacotherapeutic Treatments 
 
Sadly, of the nearly twenty million people with SUDs, SAMSHA estimated that in 2018 
90-97% of people who needed treatment received no treatment of any type including medical, 
psychiatric, or support groups.10,37 Among the small percentage of people who do seek treatment, 
there is a 40-60% relapse rate across all SUDs which is comparable to the relapse rates of many 
other well established chronic diseases.4,38 Due to the highly heterogeneous causes of SUDs and 
addictions, lack of precise diagnostic criteria for assessing true severity of the disease39, and 
inadequate training of medical professionals in the field of substance use40 it is not surprising that 
there are extremely high rates of relapse.  
Current treatments for addictions and SUDs are limited and often consist of a combination 
of behavior therapy, counseling, and medications depending on what substance an individual is 
using. Research for new pharmacotherapeutic treatments is ongoing, but currently the FDA has 
only approved medications for the treatment of alcohol, nicotine, and opioid use.5 New techniques 
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with promising results for the treatment of addictions and SUDs are being developed at increasing 
rates as the cost of these diseases continues to rise. One of these promising techniques include: 
transdiagnostic treatments, which look to treat the underlying conditions shared across behavioral 
and substance related addictions41. One promising pharmacological treatment is the development 
of the drug Topiramate that shows efficacy across SUDs.5,42  
 One area of interest is the identification of genes and biological mechanisms that could 
lead to the discovery of novel therapeutic agents. These novel biomarkers could allow medical 
professionals to assess a person’s vulnerability to SUDs, identify which pharmacotherapeutic 
techniques could be the most beneficial to an afflicted individual43, or even help determine the 
vulnerability to relapse44. Through the discovery of novel addiction genes and biological 
mechanisms, there is the potential to accelerate the rate at which we can produce improved 
therapeutic treatments, both general and individualized.  
1.6. Leveraging Mouse Models to Study Addiction Risk Behaviors 
The identification of the biological mechanisms and genetic factors underlying all stages of 
addiction and SUDs is critical for the advancement of current treatments and preventions methods. 
The vulnerability to these diseases, and an individual’s trajectory of progression from abuse to 
addiction, is strongly influenced by both genetic and environmental factors.45,46 A combination of 
family and association studies have led to limited identification of genetically heritable factors 
underlying drug-specific47 and generalized48 addiction at various stages.45–47 Previous studies have 
shown that ADH1B, ADH1C, and ALDH alter a person’s initial vulnerability to alcoholism47; 
meanwhile, other studies have shown that DRD2 and DRD4 are associated with later stages of 
alcohol use such as alcohol dependence.45 Additionally, DRD4 is associated with dependence of 
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multiple other drugs including MA, suggesting that it potentially may be a genetic factor 
underlying general mechanisms of addiction.49 In addition to their associations with various stages 
of drug use and addiction, some of the identified gene variants such as (SERT, THP1, and TPH2) 
have also been independently linked to personality traits of comorbid diseases which increase their 
vulnerability to addiction.45,47  
 Identifying these mechanisms and candidate genes in humans is a daunting task due the 
heterogeneous etiology for each individual afflicted with these diseases. With human studies it is 
almost impossible to separate a person from the innumerable environmental factors that go into 
the formation of their addictive disorder and study predisposing biological and behavioral factors 
separate from effects of the drug use. While, as stated earlier, GWAS have started to identify some 
promising candidate genes for biomarkers of addiction and SUDs they really has only started to 
scratch the surface of the genetic factors effecting addiction.  
Because there is conservation of the addiction risk reward circuitry across species5,12–14 animal 
models can be used to help fill many of the gaps in knowledge left by the limited information 
available from human studies. Using an animal models, including mice, affords many 
complementary benefits to human studies. While the total scope of addiction or SUDs could never 
be perfectly modeled using a single mouse model due to the complexity of the diseases. Mouse 
models allow control over genetic background and environmental factors, and they allow access 
to neurobiological processes to study precisely defined addiction risk phenotypes. Leveraging the 
valuable tool of mouse genetics allows for a more rapid and precise discovery of new biomarkers 
and biological mechanisms of addiction risk behaviors. 
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1.7. Predisposing Drug-Naïve Behaviors 
Genetic and genomic screens have been previously employed in mutant mouse lines in the 
hopes of identifying novel genetic biomarkers related to addiction and SUDs. One major historical 
challenge with these programs has been that they required a separate drug-naïve cohort of mice to 
avoid the effects of drug exposure on subsequent physiology and behaviors.50 These procedures, 
designed to screen candidates for their role in addiction risk phenotypes, required the application 
of expensive and complex experimental paradigms for the study of drug consumption and drug 
effects. In more recent high-throughput discovery-based approaches, by the International Mouse 
Phenotyping Consortium, large-scale screens which employ a single unified test battery are being 
used to characterize behavioral and physiological phenotypes of single gene C57BL/6NJ knockout 
strains.51 
Risk for and consequences of many aspects of addiction and SUDs are associated with 
other predisposing drug-naïve behaviors, personality traits, and co-occurring psychological 
conditions in humans.23–26 Mouse behavioral tests can be used to precisely model many aspects of 
these predisposing or co-occurring traits related to anxiety, depression, impulsivity, and novelty 
seeking.25,52,53 Previous studies have shown that these predisposing drug-naïve behaviors, which 
include approach-avoidance tasks, ‘behavioral despair’ assays, tolerance for delayed reward, and 
novelty seeking tasks can be used to predict drug-related phenotypes in the laboratory mouse.54–57 
In a similar vein, studies using inbred mouse populations have revealed that there are shared 
genetic mechanisms driving predisposing behaviors and drug-related phenotypes across distinct 
drug classes.2,3 However, many of the genes underlying the shared genetic variation among drugs, 
alcohol, and predisposing phenotypes such as novelty seeking remain unknown. This study 
attempts to exploit these proven relationships traits to identify novel addiction risk genes and 
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potential addiction-related genes through the screening of single-gene knockout strains to identify 
strains with extreme responses on phenotypes that are have been shown to be genetically correlated 

























 EXPERIMENTAL STRATEGY, MATERIALS, AND METHODS 
2.1. Overarching Experimental Strategy  
 
First, two hundred twenty-one KO strains (8F, 8M per strain) matched with C57BL/6NJ controls 
were tested in each cohort on a broad behavioral phenotyping pipeline as part of the JAX 
KOMP2 project (Sup Fig. 1). This phenotyping pipeline included open field, light dark, hole 
board, acoustic startle, and tail suspension; phenotypes from these five behavioral assays have 
been shown to predict substance use in mice.52,53,58–60 Next, from this initial group of two 
hundred twenty-one KO mouse strains, we identified the subset of KO strains (n = 19) that 
exhibited a significant difference from B6NJ controls on at least one of these five behavioral 
assays that predict substance use in mice. The measures we used to select lines and rationale for 
each is as follows:  
1) Nose-pokes (Holeboard) - The total number of nose-pokes into the sixteen holes in the 
hole board testing arena during the single twenty-minute testing session. Nose-pokes in a hole 
board is one of several genetically distinct indexes of novelty seeking53 which are positive 
predictors of substance use in mice. 56 High nose-pokes reflect high novelty seeking.  
2) Time in light (LightDark) - The total amount of time, represented as a percentage of 
total testing time, during which the mouse spent on the light side of the two-chambered light dark 
apparatus during the single twenty minute testing session. Time in light is an index of anxiety 52 
and is positively genetically correlated with substance use in mice.57 Low time in light reflects 
high anxiety and more time in light reflects excessive risk-taking.  
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3) Time immobile (Tail Suspension) - The total amount of time a mouse is immobile while 
suspended by its tail during the five minute testing session. Time immobile is recognized as an 
animal model for efficacy of antidepressants58 which has been shown to increase chances of drug 
acquisition and maintenance.25 While there may be controversy over the validity of this model as 
a depression-like behavior, many researchers still use time immobile due to its predictive 
validity.61,62 A greater time immobile is considered a measure of higher levels of depression-like 
behavior.  
4) Latency to immobility (Tail Suspension) - The total amount of time a mouse is actively 
moving while suspended by its tail before it becomes immobile during the five minute testing 
session. Latency to immobility is recognized as an animal model for the study of depression58 
which has been shown to predict increased drug acquisition and maintenance.25 Shorter latency to 
immobility reflects greater depression-like behavior.  
5) Percent PPI (Acoustic Startle) - Percentage of baseline startle response when lower-
intensity ‘prepulse’ sounds precede a louder ‘pulse’ sound. Reduced PPI is a Research Diagnostic 
Criteria (RDOC) and endophenotype for multiple neuropsychiatric disorders59 including panic 
disorder (anxiety) which is positively genetically correlated with substance use in mice 57. Reduced 
%PPI is an index for increased anxiety.  
6) Total rearing (Open Field) - The total amount of times a mouse rears or jumps during 
the twenty minute testing session in the open field arena. This endpoint serves as a measure for 
anxiety60,63 which is positively genetically correlated with substance use in mice.57 Decreased total 
rearing is an index for increased anxiety.  
7) Total distance travelled (Open Field) - Total distance travelled traveled during the 
twenty minute testing session in the open field arena. Distance traveled serves as a measure of 
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anxiety 60,63 which is positively genetically correlated with substance use in mice.57 Decreased total 
distance travelled is an index of increased anxiety. 
8) Slope of distance travelled (Open Field) - Slope of the best fit line measuring the change 
in distance traveled over the twenty minute test which is broken into four five-minute time bins. 
This measure is calculated to show habituation to the novelty which can be used to measure anxiety 
or exploratory/risk taking phenotypes.64 These behaviors are genetically correlated with substance 
use in mice.57  
9) Increased slope (increased habituation) is an index for decreased anxiety.  
Distance first five minutes (Open Field) - Total distance travelled traveled during the first 5 
minutes of the twenty minute test in the open arena. Distance traveled in the first five minutes of 
open field serves as a measure of novelty reactivity and anxiety65 which has been shown to be 
predictive of initiation of drug use and progression to compulsive drug use66 High distance 
travelled reflects high novelty reactivity and low anxiety. 
10) Center time (Open field) - The total amount of time spent in the center 40% of total 
surface area in the open arena during twenty minute testing. Time spent in the center servers as a 
measure for anxiety60,66 and is positively genetically correlated with substance use in mice.57 High 
time in the center reflects low anxiety. 
Although some strains had more extreme phenotypic values than those chosen, the validation 
of our primary screening experiment was limited to those lines that were maintained as live stocks 
and were available at the time of testing. Using a two-bottle choice assay, we quantified substance 
use (MA, EtOH, or nicotine) in mice from these nineteen KO strains (N=951) (Sup Table 1). The 
2BC paradigm was chosen because it allows for the measurement of drug consumption (mg of 
drug consumed corrected for kg of mouse), drug preference (the percentage of milliliters of drug 
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consumed out of total consumption), along with total-drinking (total amount of milliliters 
consumed) phenotypes. The total-drinking phenotype is of interest because natural variation in 
fluid consumption may serve as a biomarker of future drug use. Perturbations of the caudate have 
been associated with both changes in fluid consumption such as hyperdipsia 67 and also changes 
in drug consumption68,69 From this group of nineteen KO strains we identified strains that exhibited 
a significant difference from B6NJ controls on two-bottle choice of MA, EtOH, or nicotine. We 
then performed a functional analysis using GeneWeaver70 of gene deletions which significantly 
affected a drug-related phenotype. Next, we ran a principle component analysis in order to 
investigate the underlying shared correlation structure across addiction risk phenotypes and 
predisposing baseline behaviors.  
Following completion and validation of the initial nineteen strains, the selection process was 
modified to identify the strains that displayed the most phenodeviance overall. The use of a 
multidimensional assessment of predisposing behaviors was based on our finding that most 
extreme neurobehavioral effects of gene deletion are also associated with drug- related phenotypes, 
and that rather than make specific univariate predictions, a single multivariate based prediction 
was more straightforward and allowed us to identify the most extreme deletion effects. We 
hypothesized that looking at overall deviance of strains could improve our selection criteria and 
produce more strains with drug-related phenotypes and a greater percentage of genes that have 
significant effects on multiple drugs instead of drug specific effects. Using a Mahalanobis distance 
calculation to calculate overall phenodeviant strains, we applied this multi-dimensional approach 
to the four hundred two KO strains tested in KOMP. With these calculations we identified and 
rederived fifteen of the most deviant strains and two expert nominated strains for assessment of 
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drug-related phenotypes. Using MA 2BC and EtOH DID protocols, we screened knockouts and 
controls (N=608) (Sup Table 2, 3) for addiction risk phenotypes.  
2.2. Animal Husbandry: Behavioral Phenotyping 
 
Mice of both sexes were obtained from The Jackson Laboratory Repository at 4 to 6 weeks of age 
and transferred to the Research Animal Facility housing area by a wheeled cart. All mice were 
tested on the adult JAX KOMP2 pipeline starting at 8 weeks of age 
(www.mousephenotype.org/impress/procedures/12). Upon completion of each test, mice were 
returned to their home cage and brought back to the mouse housing room unless otherwise stated. 
Mice were housed in duplex polycarbonate cages with bedding consisting of pine shavings in 
pressurized individual ventilated (PIV) racks. The housing room was climate-controlled 71± 3° F 
humidity range 50 ± 20% set to standard 12:12 light-dark cycle and mice were provided access to 
food (NIH315K52 chow, Lab Diet 6%/PM Nutrition, St. Louis, MO, USA) and acidified water 
ad-libitum. All procedures and protocols were approved by The Jackson Laboratory Animal Care 
and Use Committee, and were conducted in compliance with the National Institutes of Health 
Guideline for Care and Use of Laboratory Animals. All testing was conducted between hours 7am 
and 5pm of the light phase.  
2.3. General Testing Procedures 
 
Mice were subjected to a battery of tests of biological and behavioral endpoints.51 Tests 
were arranged by perceived stressfulness in an effort to minimize potential carry-over effects. For 
exact details on all fifteen weeks of testing see Supplemental Fig. 1. All runs within the 
phenotyping pipeline were run in a sex specific manner, e.g. each run would either consist of all 
males or all females. Upon completion of each test all chambers were cleaned with 70% ethanol 
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between mice, and then cleaned with a scent free 1% Virkon solution at the end of the day, 
followed by a 70% ethanol rinse to remove the residue left by the Virkon. Protocols match SOPs 
used at the time of testing (2013-2015) and current updated versions can be found at 
https://www.mousephenotype.org/impress/PipelineInfo?id=7. 
2.4. Open Field 
 
The open field arena is a clear Plexiglas or acrylic box (42x42x42cm) with a dark gray 
floor, illuminated at 150-200 LUX in a 10 × 9 ft. room. Zones of the arena were set as follows – 
center 40% of total surface area; four corner zones measuring 58.06 cm2 each; peripheral zone 
measures 7.62 cm from the edge of the arena walls. The test was performed using eight Versamax 
Animal Activity Monitors (AccuScan Instruments, Inc; Columbus OH). The Friday prior to the 
testing week, mice were moved in their home cage from main housing room and placed on 
identical PIV racks within the testing room and allowed to habituate to the room for 3 days. On 
the day of testing, up to eight mice were placed randomly in one of eight empty arenas and allowed 
to explore for twenty minutes undisturbed. Activity during the test was recorded using AccuScan 
Versamax Animal Activity Monitors. Upon completion of the twenty minutes mice were removed 
from testing arena and returned to their home cage and placed back on PIV rack in testing room.  
2.5. Light/Dark 
 
The light-dark box consists of the AccuScan open field arena with an insert evenly dividing 
the arena into two equally sized compartments with the light side illuminated at 150-200 lux and 
the dark chamber at 4-7 lux. Mice were placed randomly in one of eight empty arenas on the light 
side and allowed to explore for twenty minutes undisturbed. Upon completion of the twenty 
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minutes mice were removed from testing arena and returned to their home cage and placed back 
on PIV rack in testing room.  
2.6. Holeboard 
 
The holeboard test serves to monitor the exploratory and inhibitory phenotypes over a 
defined period of time. The holeboard apparatus (AccuScan Instruments, Inc; Columbus OH) 
consists of an insert that fits into the AccuScan open field chamber consisting of 16 holes in a 4 × 
4 grid. Ambient lighting (150-200 lux) was used to encourage exploration. Subjects were randomly 
placed into 1 of 4 empty chambers and allowed to explore for 10 minutes undisturbed. Upon 
completion of the 10 minutes mice were removed from testing arena and returned to their home 
cage and placed back in the housing room.  
2.7. Acoustic Startle/Pre-pulse Inhibition 
 
The experimental apparatus consists of a load cell platform below a restraint container 
linked to a piezoelectric transducer and amplifier and housed in sound attenuated chamber (San 
Diego Instruments, Inc; San Diego, CA). A sound generator interfaced to software generate audio 
stimuli. The testing procedure includes a 5 minutes acclimation period of background noise 
followed by the presentation of trial types of the startle response (120 dB, 40 msec duration) 
presented alone or in combination with prepulses at either xx, yy, or zz dB (20 msec duration) and 
presented in a pseudorandom order (Supplemental Table 4). % prepulse inhibition is calculated as 





2.8. Tail Suspension 
 
The tail suspension test consists of a metal bar suspended on a clamp stand 36.6 cm above 
the lab bench in front of a neutral color background. Noldus Ethovision XT (Noldus, Inc; Leesburg, 
VA) behavioral tracking software interfaced with video camera was used to record individual mice 
during the test. A plastic cone cut from a 10 mL Falcon tube was placed over the tail to minimize 
the ability of mice to climb their tails and masking tape was used to gently attach the tail to the 
bar. The mouse was exposed to the suspension and recorded for a single 5 minute trial. Latency to 
immobility and time spent immobile were recorded.  
2.9. Identification of Predictive Behavioral Phenotypes: Initial Screening 
 
We performed analysis on traits that had at least a certain number of observations as 
stipulated by R/PhenStat bioconductor package (v 1.0.0).71 PhenStat is built on linear mixed-
effects model where date of test is considered the random effect with sex, genotype and the 
interaction of sex and genotype information are fixed effects terms. Missing values were ignored. 
Individual animals were tested on each assay once. Mutants were compared statistically to 
C57BL6/NJ controls found in their own testing batch. Selection of knockout strains for further 
screening on addiction risk phenotypes was based on the criteria that they at least one significant 
hit (genotype p-value < 0.05) across the ten phenotypes in addition to availability of homozygous 
null mutant lines.  
2.10.  Subjects: Initial Screening  
 
 Nineteen strains that represented the range of observed phenotypes were selected for the 
two bottle choice protocol. Strains selected from KOMP Pipeline were as follows: C57BL/6NJ-
20 
 
Btg2tm1b(KOMP)Mbp/2J, B6N(Cg)-C1qatm1b(EUCOMM)Wtsi/3J, B6N(Cg)-C9tm1.1(KOMP)Vlcg/J, B6N(Cg)-
Cfbtm1.1(KOMP)Wtsi/J, B6N(Cg)-Cptm1b(KOMP)Wtsi/J, B6N(Cg)-Dnajb3tm1.1(KOMP)Vlcg/J, C57BL/6NJ-
Dnase1l2em1(IMPC)J/J, B6N(Cg)-Epb41l4atm1b(KOMP)Mbp/2J, B6N(Cg)-Far2tm2b(KOMP)Wtsi/2J, 
B6N(Cg)-Gipc3tm1b(KOMP)Wtsi/J, B6N(Cg)-Hdac10tm1.1(KOMP)Mbp/J, B6N(Cg)-Hspb2tm1.1(KOMP)Vlcg/J, 
B6N(Cg)-Htr1atm1.1(KOMP)Vlcg/J B6N(Cg)-Il12rb2tm1.1(KOMP)Vlcg/J, B6N(Cg)-Lpar6tm1.1(KOMP)Vlcg/J, 
B6N(Cg)-Parp8tm1.1(KOMP)Wtsi/J, B6N(Cg)-Pitx3tm1.1(KOMP)Vlcg/J, B6N(Cg)-Pnmttm1.1(KOMP)Vlcg/J, 
B6N(Cg)-Rilpl2tm1b(KOMP)Wtsi/J. All strains were homozygous for their gene deletions. All mutants 
were tested relative to sex and age-matched control C57BL/6NJ mice. 
 All C57BL/6NJ controls were purchased from JAX production. C57BL/6NJ were 
maintained as their own line for the duration of our project to use as controls. While non-
littermate controls are considered approximate controls, many of the historical problems with 
using non-littermate controls in testing were addressed in this project. JAX has rigorous genetic 
quality control and mutant gene genotyping programs to ensure the genetic background of JAX® 
Mice strains. In addition to the rigorous quality control JAX also employs to maintain integrity 
of the background strains these quality control measures are also employed to maintain integrity 
of the genotypes of strains with identified molecular mutations. All KO strains used in this 
project were created using C57BL/6NJ embryonic stem cells backcrossed to at least N5 leaving 
no flanking DNA that differs from controls and mutants. Similarly, all endonuclease modified 
lines used have no flanking DNA which differs from control strain. All strains in our initial 
screen were received directly from production directly for testing. This ensured that all strains 




2.11.  Two Bottle Choice: Animal Husbandry 
 
Experimental mice were obtained from the JAX Repository and transferred to the JAX 
housing and phenotyping facility. Mice were group housed in duplex polycarbonate cages prior to 
testing. One day prior to testing, mice were individually rehoused in duplex polycarbonate cages 
with a single Shepherd Shack® and Nestlet® for the duration of testing. Duplex cages were all 
placed on conventional mouse racks. Cages were set up with two 50 mL sipper tubes on each half 
of the cage top. The sipper tubes were constructed from sterile 50 mL Polypropylene centrifuge 
tubes (#430291 Corning, Corning NY), fitted with a #6 one-holed rubber stopper (#14-135J 
Fischer-Scientific) and a 2.5 inch stainless steel sipper (Cat# SPS-SM tube 2.5 w/ball, Sta-Pure 
Systems, Carnegie PA). Mice were maintained in a climate-controlled room under a standard 12:12 
light-dark cycle (lights on at 0600 hours and off at 1800 hours) and mice were provided free access 
to food (NIH315K52 chow, Lab Diet 6%/PM Nutrition, St. Louis, MO, USA) All procedures and 
protocols were approved by JAX Animal Care and Use Committee, and were conducted in 
compliance with the National Institutes of Health Guideline for Care and Use of Laboratory 
Animals.  
2.12. Two Bottle Choice: Protocol 
 
The 2BC paradigm used three different drugs at varying concentrations: EtOH (3%, 6%, 
12%, 15%), MA (10 mg/L, 20 mg/L, 40 mg/L, 80 mg/L), and nicotine (10 mg/L, 20 mg/L, 40 
mg/L, 80 mg/L). Individual mice were only exposed to one drug for testing. Drugs were presented 
in ascending order by concentration. Subjects (N=951) normal water was replaced with sipper 
tubes filled with water for a minimum of one day to acclimate. On day one of the testing protocol, 
one sipper of water was replaced with a sipper filled with one of the three drugs diluted in sterilized 
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acidified (pH 2.5-3) water (nicotine solution also contained 20 g/L saccharine sodium salt hydrate), 
while the second sipper remained filled with water and also 20 g/L saccharine sodium salt hydrate 
(if paired with nicotine as drug). Both sippers were then weighed using an Ohaus AV212 field 
weigh scale with a tolerance of .01g (OHAUS, Corp; Parsippany, NJ). Mice were given access to 
the two bottles for 48 hours. On day three, drug and water sippers were weighed for every mouse 
and switched to the opposite side of the cage to avoid side bias. Mice were given access to both 
bottles again for 48 hours. On day five, both drug and water sippers were weighed and replaced 
with new sippers. The water sipper was replaced with a freshly filled sipper of water and the drug 
sipper was replaced with the next dose in the curve. This process was repeated for all four doses, 
giving the mice access to the drug on each side of the cage for 48 hours.  
Interpretation of 2BC results are as follows: 
Significant consumption phenotype in the absence of preference phenotype suggests that there is 
an effect for general fluid intake usually accompanied by total-drinking phenotype suggestive of 
dysregulation of fluid intake. Significant consumption and preference phenotype suggests that 
there is an alteration to avidity for the drug and selective effect on drug intake as opposed to general 
fluid intake. Finally significant preference phenotype in the absence of a consumption phenotype 
indicates a selective effect on water intake in the presence of the drugs.  
2.13. Data Analysis: Two Bottle Choice 
 
Phenodeviant KO strains were assessed for significantly altered drug-related phenotypes in 
the EtOH, MA, and Nicotine 2BC protocols using a repeated measures ANOVA. KO strains were 
assessed for significant effects of strain, sex, dose, and the interaction between them relative to the 
C57BL/6NJ controls. A threshold of FDR < 0.05 was used to test for significance of terms in the 
model. Strain and sex were between-subjects factors and dose (3%, 6%, 12%, 15%) or (10 mg/L, 
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20 mg/L, 40 mg/L, 80 mg/L) were within-subjects factors. All values were computed using the 
average of two 48 hour sessions per dose. Data lost from one session, due to leaks, was not 
corrected for and the remaining value was used. 
2.14. Principle Component Analysis 
 
Investigation of the underlying shared correlation structure across drug consumption 
phenotypes and baseline behaviors was performed using a principle component analysis. All 
genotype difference estimates were subjected to a Van der Weerden (RankZ) transformation and 
subjected to principle component analysis using R (V 3.4.4) / factoextra _1.0.5, fviz_pca_biplot(). 
We extracted the first two PCs to assess the relationships among the predisposing behaviors, drug 
related behaviors and to assess the location of each knockout strain in this two-dimensional space 
constructed from the measured variables.  
2.15. Calculating Mahalanobis Distance of Predisposing Behaviors 
 
To assess overall phenodeviance measures from Open Field, Light/Dark, Holeboard, and 
Acoustic startle were used to calculate Mahalanobis distance for all tested strains compared to 
C57BL/6NJ controls. Mahalanobis identifies strains that are multivariate outliers through the 
calculation of the distance from the centroid, representative of control strain values, in a 
multidimensional space using the values from the nine predisposing behavioral traits.72 We used 
R/Phenstat bioconductor package (v 1.0.0)71 for modeling the association between trait and 
genotype. Genotype effect estimates were then used for Mahalanobis distance calculations 
following a rankZ transformation. Multivariate outliers were identified using the Mahalanobis 
distance. Outliers were defined by the distance of the data point from the calculated centroid of 
the other observations in multivariate space. The centroid is defined as the intersection of the mean 
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of the variables being assessed. The Mahalanobis distance follows a 𝜒2 distribution, which is used 
to assess statistical significance.72 Tail suspension was not used in Mahalanobis calculations 
because it was dropped from KOMP2 testing and would have greatly reduced the number of strains 
with complete data for the second screening analysis. Using these results, we identified one 
hundred thirty-three as significantly phenodeviant from the C57BL/6NJ controls.  
2.16. Subjects: Second Screen 
 
Fifteen strains were selected for their significant phenodeviance: B6N(Cg)-
Elof1tm1.1(KOMP)Vlcg/J(+/-), C57BL/6NJ-Stk36em1(IMPC)J/J(-/-), C57BL/6NJ-Myh10em1(IMPC)J/J(+/-), 
B6N(Cg)-Dnmt3atm1b(KOMP)Wtsi/J(+/-), B6N(Cg)-Cptm1b(KOMP)Wtsi/J(-/-), B6N(Cg)-
Zbtb4tm1.1(KOMP)Vlcg/J(-/-), B6N(Cg)-Dnaja4tm1b(KOMP)Wtsi/J(-/-), B6N(Cg)-Irf8tm1b(KOMP)Wtsi/J(-/-), 
B6N(Cg)-Htr7tm1b(KOMP)Wtsi/J(-/-), B6N(Cg)-Gpr142tm1.1(KOMP)Vlcg/J(-/-), B6N(Cg)-C3tm1.1(KOMP)Vlcg/J(-
/-), B6N(Cg)-Rap2btm1.1(KOMP)Vlcg/J(+/-), B6N(Cg)-Tmod2tm1b(KOMP)Wtsi/2J(-/-), B6N(Cg)-
Stx19tm1.1(KOMP)Vlcg/2J(-/-), B6N(Cg)-Lrrc15tm1b(KOMP)Wtsi/J(-/-). Six expert nominated strains were 
also tested.  
Expert nominated strains derived from the C57BL/6NJ line were B6N(Cg)-
Nr2f1tm1.1(KOMP)Mbp/J(+/-), C57BL/6NTac-Trib3tm1a(EUCOMM)Hmgu/IcsOrlEjc(-/-). In addition to 
C57BL/6NJ strains expert nominated strains derived from the C57BL/6J line were C57BL/6J-
Bmerb1em1Ejc/Ejc (-/-), C57BL/6J-Taar1em1Ejc/Ejc (D2KI) (B6J-Taar1), and C57BL/6J-
Fam53b<em5Ejc>/Ejc. All C57BL/6J derived strains were tested against contemporaneously 
characterized C57BL/6J controls. Expert nominated strain derived from the DBA/2J line was 
DBA/2J-Taar1em2 Ejc/Ejc (B6KI) (DBA-Taar1). All DBA/2J derived strains where tested against 
DBA/2J controls. C57BL/6J-Taar1(D2KI) and DBA/2J-Taar1(B6KI) are both CRISPR knock-in (KI) 
strains with functional versions of Taar1 alleles swapped.  
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All mutants were tested using sex and age matched C57BL/6NJ controls that were 
housed in the same breeding room as the mutant colonies. All mutants in the second screen were 
procured in the same manner as strains in our initial screen with the exception that mutants were 
received as heterozygous mutants and bred in lab to homozygous when possible. Strain 
maintained in our colony were bred to no greater than F5 to avoid genetic drift from production 
colonies.  
2.17. Drinking in the Dark/ Second 2BC: Animal Husbandry 
 
Chosen strains were obtained from the JAX Breeding and Rederivation Services and 
transferred to the JAX housing and phenotyping facility where they were bred to testable cohort 
size through pair and trio mating. Homozygous viable strains were bred using hom × hom breeding 
pairs or trios (1M, 2F). Homozygous lethal strains were bred using het × het breeding pairs or trios. 
Mice were housed in duplex polycarbonate cages with bedding consisting of pine shavings in 
pressurized individual ventilated (PIV) racks. The housing room was climate-controlled 71± 3° F 
humidity range 50 ± 20% set to standard 12:12 light-dark cycle and mice were provided access to 
food (NIH315K52 chow, Lab Diet 6%/PM Nutrition, St. Louis, MO, USA) and acidified water 
ad-libitum. All procedures and protocols were approved by JAX Animal Care and Use Committee, 
and were conducted in compliance with the National Institutes of Health Guideline for Care and 
Use of Laboratory Animals. Mice were group housed in duplex polycarbonate cages prior to 
testing. Twenty-four days prior to testing all mice were housed individually in duplex 
polycarbonate cages with a single Shepherd Shacks® and Nestlets® and remained so throughout 
all testing. Duplex cages were all placed on conventional mouse racks. Cages were set up with 
standard Lab Diet 6%/PM Nutrition, and acidified water ad libitum. Mice were maintained in a 
climate-controlled room under a reversed 12:12 light-dark cycle (lights on at 2000 hours and off 
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at 800 hours). All procedures and protocols were approved by JAX Animal Care and Use 
Committee, and were conducted in compliance with the National Institutes of Health Guideline 
for Care and Use of Laboratory Animals. At time of testing acidified water was replaced with 20% 
EtOH sipper for two to four hours. Sippers were created from 2.5 inch stainless steel sipper (Cat# 
SPS-SM tube 2.5 w/ball, Sta-Pure Systems, Carnegie PA), 10 mL Disposable Polystyrene 
Serological Pipette (Fischer Scientific , Agawam MA), and shrink wrap. 
2.18. Drinking in the Dark: Protocol 
 
All strains chosen for this second screening were tested for MA and EtOH phenotypes. The 
MA 2BC protocol was left unchanged, but for EtOH the Drinking in the Dark (DID) paradigm 
was used instead. DID is a protocol that was developed as a binge drinking paradigm in mice. 
Binge drinking is classified as dangerous amounts of alcohol consumption leading to a blood 
ethanol content (BEC) 80 mg/dL73 which leads to an increased risk of alcohol use disorder.74,75 
Normally, mice do not drink sufficient EtOH to become intoxicated.76 Using limited access during 
a time in the circadian cycle when mice are behaviorally active results in a level of consumption 
leading to intoxication.77–79 From this protocol we can get measures of four day consumption and 
measures of BEC.  
Testing was done using a modified DID protocol.79 All testing is done in a dark room, with 
red lights. The DID paradigm used 20% EtOH made from mix of 100% EtOH and acidified 
drinking water. Individually housed transgenic mice and controls (N=608) chosen for testing were 
habituated for twenty-four days to reverse light cycle and weighed before lights off on first of four 
day of testing. Weights were recorded for all mice on the first day of the protocol during the lights 
on phase. New EtOH solution was prepared every day of testing. At 1100 hours the initial starting 
volume for each sipper were measured to the closest .05 mL along with initial starting weights 
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which were measured to the nearest .01 g and recorded in excel. Following initial recordings of 
volume and weight, sippers were put into cages in place of water with a two minute stagger 
between mice. Once all mice had received sippers, two control sippers were set up in an empty 
cage to be used as standards for evaporation and leakage. On days one through three, the mice had 
access to EtOH for two hours. At 1300 hours sippers were collected, weighed, and acidified water 
was returned to cage. Sippers were collected and weighed at the same pace they were distributed. 
On day four mice had access to EtOH for four hours. Sippers were administered to mice one at a 
time with a three minute stagger between mice. At 1500 hours sippers were collected for 
assessment of final volumes and weights. Finally, as sippers were removed, blood samples were 
taken from mice using a cheek bleed technique for assessment of BEC.  
2.19. Blood Collection 
 
 A minimum of 50 µL of blood was collected into a microtainer (purchased from VWR, 
cat.# VT365956) immediately following ethanol removal. Blood samples were then spun at 13,300 
RPM for 11 minutes, and serum was pipetted into separate Eppendorf tubes on dry ice within one 
hour of collection. Once all samples were collected they were transferred to a -80°C freezer within 
three hours of blood being drawn. Samples were brought to JAX Clinical Chemistry for analysis.  
2.20. Data Quality Control and Analysis of the Second Screen  
 
Removal of outliers was done on a strain × sex × dose basis. Means were calculated on a 
strain × sex × dose basis and data points which fell more than two standard deviations outside the 
mean were considered outliers and removed.  
We applied a repeated measures ANOVA to each of the MA phenotypes to assess the strain 
× sex × dose effects, in addition to assessing strain and strain × sex effects. After fitting each 
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model, we obtained the least squares mean difference between each knock-out relative to the 
C57BL/6NJ controls. A threshold of FDR < 0.05 was used to test for significance of terms in the 
model. Of particular interest were strain, strain × dose, and strain × dose × sex effects.  
A repeated-measures ANOVA was also applied to EtOH consumption in DID protocol to 
assess the strain × sex effects, in addition to assessing strain effects. Following the model fit, we 
obtained least squares mean difference between each knock-out relative to the C57BL/6NJ control. 
A threshold of FDR < 0.05 was used to determine significance of terms in the model. Of particular 
interest were strain, and strain × sex effects.  
Analysis of BEC was done using a two-way ANOVA. Tukey’s Honestly Significant 


















3.1. Results: Initial Screening of Drug-Naïve Behavioral Phenotyping  
 
To assess performances on the ten predisposing behaviors measured in the KOMP2 pipeline, 
we performed analysis using R/PhenStat bioconductor package (v 1.0.0)71 on strains which met 
the threshold for minimum number of observations for each test. Strains with insufficient replicates 
were omitted from the analysis. Results from the initial screen of predisposing behaviors revealed 
that about two thirds of the strains (64.7%; n= 143) were phenodeviant (deviant from C57BL/6NJ 
controls on at least one behavioral trait) on at least one of the ten predictive behaviors p< .05. 
Strains with extreme phenotypes and or multiple phenodeviant behaviors were prioritized in our 
selection process, but selection was limited to strains that were alive and available at the time of 
testing. Initial screening of available KOMP2 data led to the selection of nineteen strains to assess 
for drug-related phenotypes. While selected strains do not represent the most phenodeviant 














3.2. Results: Initial Two Bottle Choice Screening 
 
The selection process successfully identified single gene KO strains with differential drug-
related phenotypes relative to controls. Fifteen of the nineteen strains resulted in a significant 
phenotypic difference of strain, or strain × dose across either MA or EtOH. (Fig 1a,b). Of the 
Figure 1: Phenotypic allele variation in drug-naïve behaviors for initial screening. Thick black bars 
represent Rank score for C57BL6/NJ controls. Colored bars represent the 19 phenodeviant strains predictive of 
addiction risk phenotypes. Gray bars represent the ranked genotype effects on each measure calculated across 
the approximately four hundred two knockout strains tested as of April, 2016. Rank Z graphs display where the 
nineteen strains chosen for initial screening out of the first two hundred twenty-one strains fall in the range of 
the four hundred two strains measured for second screening. Strains were chosen based on availability, and 
significant (p < 0.05) phenodeviance on at least one predisposing trait. Strains labeled with a black diamond 
retained significant phenodeviance after addition of one hundred eighty-one new strains and multiple testing 
corrections (q < 0.05). 
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eighteen strains tested on the EtOH 2BC protocol, slightly over three quarters of them (n=14; 
77.8%) displayed significantly altered EtOH-related phenotypes either through altered preference 
or consumption (mg/kg). Six of these fourteen strains showed significant changes in both 
consumption and preference. Single gene deletions led to varying profiles of EtOH consumption, 
Il12rb2 and Far2 exemplify the range of diverse effects measured in the 2BC protocol (Fig. 1c-f). 
Deletion of Il12rb2 resulted in increased EtOH preference (Fstrain (1, 90) = 35.7, FDR= 8.63E-07) 
and also increased EtOH consumption (Fstrain (1, 90) = 88.48, FDR=9.28E-14) compared to 
C57BL/6NJ controls (Fig. 1c,d). Deletion of Far2 resulted in the opposite effects and significantly 
decreased both EtOH preference (Fstrain (1,87) = 12.31, FDR=3.40E-3) and EtOH consumption (Sup 
Panel 1). (Fstrain (1,87) = 9.3, FDR=6.40E-3). For most strains, females displayed higher levels of 
preference and consumption for EtOH than males (Sup Panel 2). 
 The initial screening process was also successful at selecting strains which displayed altered 
MA use. Seventeen strains were tested for altered MA-related phenotypes and just under one fifth 
of the strains (n=3; 17.8%) showed significantly altered preference (Sup Panel 3) or consumption 
(Sup Panel 4). While Il12rb2 and Far2 deletions led to opposing EtOH phenotypes, both deletions 
led to significantly increased consumption of MA (Fstrain (1, 71) = 9.88, FDR=2.19E-02) and (Fstrain 
(1, 69)= 10.59, FDR=2.19E-02) respectively. (Fig. 2 g, h) The only deletion to result in an altered 
MA preference was Dnase1l2 (Fstrain × dose (3, 207) = 5.07, FDR=3.75E-02) which drastically reduced 
preference for MA at the initial dose.  
Results from initial 2BC screening indicate that none of the gene knockouts altered any 
nicotine related phenotypes in the 2BC protocol. Knockouts showed non-significantly altered 










3.3. Results: Principle Component Analysis 
 
A principle component analysis was run to assess the relationships within and between our 
ten measured predisposing traits and our three drug-related traits across three drugs. A bi-plot 
clustering was then performed using the effect sizes across predisposing and drug-related traits of 
the sixteen knockout strains which were tested on all nineteen measures. Figure 3 depicts the 
Figure 2. Shared associations of gene deletion mutations with alcohol, methamphetamine and 
nicotine intake phenotypes. A,B, Bipartite graphs depicting significant effects of strain and strain × dose 
respectively across all three tested drugs. Significant associations are represented by the thickness of the 
edge connecting the two nodes. Edge weights are inversely proportional to the –log10 p-value of the 
association. Among the addiction-relevant phenotypes, ethanol consumption shows the highest number of 
significant associations. Among the gene KOs, Il12rb and Far2 showed significant effects across three 
drug-related phenotypes across two drugs, both suggestive of pleiotropy. A single gene, Hdac10, exhibited 
significant genotype × sex effects. (not depicted) C,D, Graphs depict the three significant phenotypes 
measured for Il12rb and Far2 respectively. Deletion of Il12rb resulted in increased EtOH preference and 
consumption and also increased MA consumption at higher doses. (FDR<.05) Deletion of Far2 resulted in 






results of our PCA where each gene knockout falls in the multivariate space of our two strongest 
principal components score vectors. 80 Results from our PCA reveal that using our first two 
principal components we can account for 21.1% of the variance with principal component 1 (PC1) 
and 17.8% with principal component two (PC2). Using both these PCs we can account for ~ 39% 
of the variation seen in our sixteen strains across the twenty-two measures. The correlations within 
and between any of the predisposing behavioral and drug-related traits can be assessed using the 
angle which separates any two vectors (Fig. 3). Vectors which fall close to one another are strongly 
positively correlated, vectors which fall 180° apart are strongly negatively correlated, and vectors 
which fall 90° apart are independent of one another.81 Using these relationships we can use the 
PC1 axis to separate our tested strains into ones which increased EtOH consuming/preferring 
phenotypes from those who decreased EtOH consuming/preferring phenotypes. Along the PC2 
axis we see clustering of predisposing traits which can be used to divide our strains into different 
baseline behavioral profiles i.e. “low anxiety” and “exploratory” profiles. Also along PC2 we see 
a close relationship which can separate our MA consuming strains from our non-consuming 
strains. Scores for each of the strains are obtained by multiplying the PC loadings by the strain 
means, allowing strains to be plotted in the two dimensional space. Strains with high absolute 
scores on PC1 such as Hdac10 and Dnajb3 have strong EtOH preferring/consumption phenotypes. 
Strains such as Il12rb2 and Far2 whose variation is strongly explained by PC2 would be strains 














Figure 3. Shared relationships among drug- naïve behaviors with drug related phenotypes. Principal 
components analysis was used to assess shared variance among predictive behavioral traits and drug related 
phenotypes. Each point represents a KO strain, while arrows represent drug-naïve and drug intake related traits. 
We observe clusters of gene KOs along with clusters of drug-naïve and drug intake traits indicative of shared 
relationships. PC1 explains 21.1% of the shared variance and helps differentiate KO strains with ethanol drinking 
from those that display a non-ethanol drinking phenotype. PC2, which explains 17.8% of the variance, allows us 
to categorize and relate ethanol drinking KO strains to drug-naïve behavioral profiles of risk taking versus 
exploration. These relationships reveal the multiple mechanisms by which basal behavioral variations are 
associated with drug intake behaviors. This shared variation allows us to exploit baseline behaviors towards 
identification of novel drug intake genes. Analysis was run using only the sixteen strains that were tested on all 
behavioral phenotyping measures along with being tested on all three drugs. (Colors are added to drug 
phenotypes to match color scheme from figure 2) 
 
 
HB: Holeboard, LD-LSTS: LightDark time spent in light, THP: Total hole pokes, OF-CPT: Center Permanence 
Time, OF-DTFirst5: Distance Traveled First Five Minutes, OF-DTSlope: Distance Traveled Slope, OF-DTTotal: 
Distance Traveled Total, OF-NRT: Number of Rears Total, SR-GPPIPCT: Amplitude Percent PPI Global, TS-
LI: Latency to immobility, TS-TI: Time immobile, Ethanol-DW: Ethanol Consumed, Meth-DW: Meth 
Consumed, Nicotine-DW: Nicotine Consumed, Ethanol-PREF: Preference Ethanol, Meth-PREF: Preference 
Meth, Nicotine-PREF: Preference Nicotine, Ethanol-TOTD: Total Drinking Ethanol, Meth-TOTD: Total 
Drinking Meth, Nicotine-TOTD: Total Drinking Nicotine, Ethanol-DWATER: Water Drinking Ethanol, Meth- 




3.4. Results: Phenodeviant Strain Identification in Second Screening  
 
Knockout strains were selected for second screening based on overall phenodeviance across 
traits from the open field, light dark, holeboard, and acoustic startle. As of April 2016, four hundred 
two strains had completed the phenotyping pipeline and were included in the analysis. Calculation 
of overall phenodeviance was done using Mahalanobis Distances72 of effect sizes relative to 
C57BL/6NJ controls. Results from analysis indicate that of the four hundred two single gene 
knockout strains tested, one hundred twenty-three strains were significantly phenodeviant with 
scores ranging from 24.1- 2038.9. Strains with the highest scores were prioritized for rederivation 
and screening for drug-related phenotypes. Thirteen of the most extremely phenodeviant strains 
were successfully rederived and bred for testing (Fig. 4). Two additional KOMP strains on the 
lower end of the significant scores (288 and 115) were selected for a combination of 
phenodeviance and prior biological evidence for their role in drug-related phenotypes. Finally, six 








3.5. Results: Second Methamphetamine Two Bottle Choice Screening 
 
In our initial screening of the seventeen strains tested on MA 2BC, three strains had altered 
consumption or preference attributed to main effects of strain or strain × dose respectively 
(FDR<.05). Sex had no significant effect on any of the measures of MA use; sex only had a main 
effect on the total-drinking phenotypes (mLs/kg). Results from second screening for predicted MA 
Figure 4: Multidimensional assessment of phenodeviance in drug-naïve behaviors. Of the four 
hundred two strains tested as of April, 2016, the 123 points indicate knockout strains with a statistically 
significant difference from matched C57BL6/NJ controls using Mahalanobis score (FDR < 0.05). Red 
points represent single gene knockout strains that were overall phenodeviant but not chosen for 
rederivation. Blue points represent strains that were chosen for rederivation. All blue points are 




2BC effects indicates that eight of the fifteen tested strains had significantly altered patterns of 
MA use, either manifested through a main effect of strain and or strain × dose across preference 
and consumption (mg/kg) phenotypes (FDR <.05). Six of the fifteen gene deletions resulted in a 
main effect of strain and increased preference for MA in various patterns compared to the 
C57BL/6NJ strain. Five gene deletions resulted in strain × dose effects, three of which also had 
main effects of strain, altered preference to MA in a dose dependent manner compared to the 
control strain.  
Three gene deletions, Rap2b, Tmod2, and Irf8 all showed an increase in MA consumption 
compared to the wild type control. Deletion of Irf8 gene resulted in increased preference for MA 
across doses (Fstrain (1, 51) = 12.34, FDR= 5.33E-03) compared to control strains (Fig 5A). Deletion 
of Irf8 also significantly increased preference to initial lower doses of 10 mg/L and 20 mg/L 55.1% 
±6.5 and 40.0% ±6.4 respectively, and did not display differences from control strains at higher 
doses (Fstrain × dose (3, 140) = 3.69, FDR= 4.59E-02). While all three strains had increased overall 
patterns of consumption and were also strains which had significantly increased overall preference, 
the gene deletion which most significantly increased MA consumption was Rap2b that displayed 
increased consumption on every dose (Fstrain (1, 51) = 15.14, FDR= 4.95E-03) (Fig 5b). In total, eight 
of the fifteen strains altered MA-related phenotypes, either through changes in preference or 
consumption, and an additional five knockouts altered total-drinking phenotype (FDR <.05). One 
of the two expert nominated C57BL/6NJ lines display significant alterations to MA consumption 
or preference. Trib3 displayed increased consumption at the final dose compared to controls (Fstrain 
× dose (3, 152) = 3.09, p= 2.88E-03). Nr2f1 strain displayed no significant MA phenotypes.  
Of the five non C57BL/6NJ expert nominated strains, three strains had significantly altered 
MA phenotypes. DBA/2J-Taar1(B6KI) and C57BL/6J-Taar1(D2KI) strains each displayed significant 
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alterations of both MA consumption (mg/kg) and preference (p<.05) (Fig 5C-F). DBA/2J-
Taar1(B6KI) female KIs rapidly decreased their preference to MA as doses increased, while male 
preference only gradually decreased as doses increased (Fsex (1, 28) = 4.82, p= 3.65E-02). KI of B6 
alleles into the DBA/2J strain also resulted in a significantly decreased preference to MA (Fstrain (1, 
28) = 17.66, p= 2.43E-04). (Fig. 5C) No main effect of sex was detected for MA consumption. 
DBA/2J-Taar1(B6KI) had significantly decreased MA consumption compared to control DBA/2J 
strains (Fstrain (1, 28) = 31.79, p= 4.86E-06). As drug concentration increased Taar1 mutants had a 
decrease in consumption compared to the DBA/2J control (Fstrain × dose (3, 78) = 7.39, p= 2.01E-04) 
(Fig.5D).  
KI of D2 alleles into the C57BL/6J strain resulted in a significantly increased preference for 
MA, (Fstrain (1, 19) = 20.63, p= 2.23E-04) (Fig. 5E). C57BL/6J-Taar1
(D2KI) displayed increased 
preference relative to controls as the dose increased. (Fstrain × dose (3, 55) = 4.7, p= 5.40E-03). No main 
effect of sex was detected for MA consumption. C57BL/6J-Taar1(D2KI) also resulted in 
significantly increased MA consumption compared to C57BL/6J control strain (Fstrain (1, 19)= 31.5, 
p= 2.06E-05). The C57BL/6J-Taar1(D2KI) strain showed an increase of MA consumption compared 
to the C57BL/6J controls in a strain by dose fashion (Fstrain × dose (3, 53) = 14.63, p= 4.63E-07) 
(Fig.5F).  
Expert nominated strain Bmerb1 showed increased consumption at the 40 mg/L dose and 
decreased at 80 mg/L, 2.65 ± 0.46 mg/kg and 3.29 ± 0.39 mg/kg respectively, compared to the 
control strain 1.80 ± 0.16 mg/kg and 4.60 ± 0.45 mg/kg respectively (Fstrain × dose (3, 54) = 3.32, p= 
2.64E-02) (Sup Panel 5). Additionally, Bmerb1 displayed increased preference at 40 mg/L and 
decreased preference at 80 mg/L, 32.7 ± 2.3% and 16.2 ± 2.2% respectively compared to controls 
20.7 ± 7.1% and 28.8 ± 4.2% respectively (Fstrain × dose (3, 53) = 4.5, p= 6.85E-03) (Sup Panel 6). 
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Finally, Bmerb1 was the only strain to display a sex difference on a MA-related phenotype. Male 








Figure 5. Single gene knockouts resulting in significant methamphetamine effects. A,B, Line graphs of 
preference for MA by dose. Single gene deletions of Tmod2 and Rap2b both resulted in increased 
preference for MA with main effects of strain. FDR<.05 C,D, Swapping of the Taar1 allele from non-
functional to functional version in DBA/2J background alleviated increased MA preference and 
consumption across all doses. E,F, Swapping of the Taar1 allele from functional to non-functional version 
in C57BL/6J induced the increased preference and consumption across all doses normally observed in the 
high MA consuming DBA/2J lines. 
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3.6. Results: Drinking in the Dark  
 
Analysis of DID results indicate that six of the fifteen phenodeviant strains displayed 
significantly altered consumption (mg/kg). EtOH consumption (mg/kg) was strongly influenced 
by sex in all strains with a minimum main effect of sex (Fsex (1, 47) = 40.33, FDR= 7.92E-08). Two 
phenodeviant strains, Irf8 (Fig 6A) and Elof1 (Sup Panel 7), had significantly altered EtOH 
consumption across the four days of access (Fstrain (1, 48) = 13.38, FDR= 5.37E-03) and (Fstrain (1, 48) 
= 7.6, FDR= 4.66E-02) respectively. Additionally for two strains, Zbtb4 (Fig 6B) and Tmod2, 
EtOH consumption was influenced by strain and sex (Fstrain × sex (1, 48) = 11.72, FDR= 2.17E-02) and 
(F strain × sex (1, 47) = 8.39, FDR= 4.84E-02) respectively. Similar to what was observed in EtOH 
consumption phenotype, BEC was also influenced by sex in all strains as indicated by a minimum 
main effect of sex (Fsex (1, 46) = 6.31, p= 1.56E-02). Of the fifteen phenodeviant strains chosen for 
testing in the DID paradigm no strain resulted in a significantly altered BEC. 
 Of the five expert nominated strains, only Nr2f1 affected EtOH phenotypes in the DID paradigm. 
Deletion of Nr2f1resulted in significantly decreased consumption compared to control strain (Fstrain 
(1, 47) = 38.21, FDR= 2.43E-06), and also significantly decreased BEC following four hour access 
on the final day of testing (Fstrain (1, 42) = 5.35, p= 2.51E-02). 
All C57BL/6J derived strains reach BEC levels above 100 mg/dL, but no strain was 
significantly different from control strains as indicated by significant effect of strain. The only 
observed difference was increased BEC levels in Male Fam53b males (Fstrain × sex (1, 29) = 4.46, p= 
4.34E-02). This resulted in an increase in average BEC from 54.3±17.6 mg/dL in controls to 
105.2±13.5 mg/dL in KOs.  
The DID protocol was developed to induce binge-like drinking in non-dependent 
C57BL/6J mice. In our experiment C57BL/6J consumed on average 7.21±0.54 mg/kg on day four 
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resulting in an average BEC of 108.7 ± 16.8. On the final day of testing, female C57BL/6J 
consumed more and resulted in higher BEC 9.58 ± 0.37 mg/kg and 163.2 ± 15.0 mg/dL 
respectively, than males 4.84 ± 0.39 mg/kg and 54.3 ± 17.6 mg/dL respectively. Results from our 
study show the protocol did not induce C57BL/6NJ to reach translationally relevant levels of BEC. 
C57BL/6NJ consumed on average 6.38 ± 0.54 mg/kg on day four resulting in an average BEC of 
51. ± 8.5 mg/dL. Similar to C57BL/6J, female C57BL/6J consumed more and resulted in higher 
BEC 9.03 ± 0.44 mg/kg and 76.8 ± 18.1 mg/dL respectively, than males 3.73 ± 0.37 mg/kg and 
25.2 ± 5.95 mg/dL respectively. For overall consumption, final day consumption, and BEC, 
measures from C57BL/6J were significantly higher than C57BL/6NJ (Fstrain (1, 52) = 24.05, p= 












Figure 6. Single gene knockouts and their effects on binge drinking A,B, Line graph of average strain 
consumption(mg/kg) by day in the DID protocol separated by sex. Both gene deletions also significantly 
altered total ethanol consumption across the four day DID protocol. Deletion of Irf8 resulted in a decrease 
consumption across both strains (main effect of strain FDR<.05) which was more extreme in the females. 
Deletion of Zbtb4 had a significant strain × sex effect and decrease female consumptions while mildly 
increasing male consumption. FDR<.05  C, Two dimensional circle graph summarizing the effects of the 17 
single gene deletions on average strain BEC’s following DID protocol. X dimension represents mean male 
BEC, and Y dimension represents mean Female BEC average. Grid lines intersect at the average female and 
male BECs for C57BL/6NJ controls. The radius of the circle equals the standard error for each strain black 





3.7. Results: Genes with Drug Specific or Multi-Drug Effects  
 
Using a multidimensional assessment of phenodeviance across predisposing drug-naïve 
behaviors we identified fifteen single gene  KO strains as phenodeviant, and tested them for altered 
patterns of drug-related phenotypes. Results from MA 2BC and EtOH DID revealed that two thirds 
(66.6%, 10/15) of the identified single gene deletions altered drug-related phenotypes. Further 
assessment of the ten gene deletions that altered drug-related phenotypes reveals that thirty percent 
(30%, 3/10) had multi-drug effects across both drugs and testing protocols. Results from the 
second screening indicate that ten strains showed altered patterns of drug-related phenotypes, 
seven of which were drug specific, and three of which were significant effects across both drugs 
and testing paradigms (Fig 7). 
Expert nominated strains Bmerb1 and Fam53b were only tested on one of the two protocols 
and could not be assessed for multi-drug effects. Of the six expert nominated strains, four had drug 
specific effects altering either MA or EtOH consumption. None of the expert nominated strains 






























Figure 7. Bipartite graph depicting significantly altered drug use phenotypes. Bipartite graph displays 
significant hits across the five measured phenotypes. Graph depicts significant effect of strain. Significant 
associations are represented by the thickness of the edge connecting the two nodes. Edge weights are 





4.1. Identification of Novel Addiction Risk Genes 
 
Through this project, we were able to successfully circumvent many of the challenges that 
genomic assays have historically faced and identified novel addiction risk genes in a truly 
discovery based manner. Leveraging the high-throughput KOMP phenotyping pipeline in 
combination with the known relationship underlying drug-naïve behaviors and drug-related 
phenotypes 54–57 we successfully identified twenty-five novel genes influencing both affective 
behavior and initial, non-dependent drug-related phenotypes. Fifteen of our novel addiction risk 
genes came from our initial screening where we made uniformed predictions that specific 
predisposing traits would lead to specific drug-related phenotypes. Interestingly, while we did 
successfully identify novel addiction risk genes at a high percentage, our predictions of their 
specific drug-related phenotypes were not as accurate. These results informed us that there are 
not uniform connections between drug-related phenotypes and their predisposing traits50,82–84 but 
a diverse multidimensional nature of the relations. Using these complex relations we were able to 
modify our selection process leading to the identification ten more novel addiction risk genes. 
While our prediction rate was not as high as our initial screening we were able to identify genes 
which significantly altered drug-related phenotypes across multiple drugs. This is particularly 
important because the multi-drug effects mean that these genes may play roles underlying 




4.2. Selection of Phenodeviant Strains: Initial Screening 
 
In our initial screening for addiction risk candidate genes we analyzed drug-naïve phenotypes 
gathered from all two hundred twenty-one mice tested in the KOMP2 behavioral phenotyping 
pipeline and identified nineteen strains which exhibited a significantly deviant (p < .05) novelty-
response, anxiety-related, and or depression-related phenotypes. Although many strains had more 
extreme phenotypic values than those chosen for further testing, our validation experiments were 
limited to those lines that were available at the time of testing. While strains chosen for testing in 
initial screening were not the most phenodeviant strains, they display a representative range of 
phenotypes observed on all the measures used (Fig.1).  
Using the predictive traits like anxiety, depression, exploration/novelty seeking we hoped to 
identify genes that had drug specific effects based on their baseline behavioral profile. While 
strains were selected for phenodeviance on a single trait strains of the greatest interest include 
those that were phenodeviant across multiple phenotypes i.e. Far2, which showed phenodeviance 
in five separate traits across three separate behavioral tests. We hypothesized that animals that 
showed many anxiety behaviors would manifest EtOH phenotypes, depression to nicotine, and 
novelty seeking to MA. Genes like Far2 were predicted to result in multiple phenotypes.  
4.3. Validation of Strain Identification Using Two Bottle Choice Paradigm 
 
The 2BC paradigm, also known as free choice drinking, was chosen because of its high face 
and construct validity for voluntary moderate alcohol use85,86, and it is a high throughput protocol 
which allows for the measurement multiple drug intake phenotypes. Using the 2BC protocol, we 
can measure drug consumption (mg of drug consumed corrected for kg of mouse), drug preference 
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(the percentage of milliliters of drug consumed out of total consumption), along with total-drinking 
(total amount of milliliters consumed).  
  Results from the initial 2BC screening indicated that eighteen of the nineteen tested 
knockouts exhibited a significant effect of either strain or strain × dose (FDR < 0.05) on at least 
one of the three measured phenotypes (Fig 2; Supplementary table 2). All significant effects either 
altered EtOH phenotypes, MA phenotypes, or both. Using the 2BC protocol we were unable to 
detect any significant genotype associated effects for oral nicotine related phenotypes. These 
findings could be due to the aversive taste of oral nicotine, a confounding of saccharine with the 
nicotine, or could reflect low genetic effect size for the measured phenotypes most likely due to 
complexity of the nicotine’s pharmacology both in terms of dose-response but also temporal 
patterns.5,87,88 Only one gene, Hdac10, exhibited significant genotype × sex effect on the ethanol 
total-drinking phenotype.  
In our initial screening, fifteen of the nineteen tested strains had a significant effect on the 
MA, EtOH, or both phenotypes either through alteration of their consumption or preference. 
Thirteen of the strains exhibited drug specific effects, and two had multi-drug effects altering both 
alcohol and MA phenotypes. In the field of addiction, much of the focus has gone into studying 
genetic components underlying drug-specific effects2,45,89–92 through alteration of drug-specific 
metabolism or drug receptors in the reward pathway. These genetic components can play crucial 
roles in development of treatments for drug-specific SUDs. Along with these genes that play a role 
in drug specific responses, we are also interested in our genes which had multi-drug effects, 
implying they may play larger roles underlying generalized drug-related phenotypes.  
  As a good example of multi-drug effects, the Il12rb2 knockout strain was associated with 
significant genotype and genotype × dose effect across EtOH preference, ethanol consumption, 
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and MA consumption. This suggests that while Il12rb2 has mainly been annotated for its role in 
immune response and T-helper cell differentiation93, it may also have a significant role underlying 
the reaction to drugs through unknown mechanisms and pathways. 
 Similar to what is found in the literature94,95 and results from SAMHSA’s 2018 findings 
that one third of all people suffering from illicit drug use disorders (IDUD) also suffer from AUDs, 
we found that two thirds of the knockout strains which exhibited significant effects on MA 
drinking also had a significant effect on alcohol related traits. This is consistent with 
epidemiological studies which reveal a high rate of polysubstance use such that alcohol use 
accompanies most other drug use.96 All eighteen of the knockout strains that had significant drug 
or alcohol phenotypes warrant further characterization with advanced neuroscientific and 
addiction assays. This is especially the case for genes such as Il12rb2 and Far2, which were found 
to have significant effects on both drug-seeking and addiction risk phenotypes across both ethanol 
and MA, suggesting that these may play an important underlying role in drug-related behaviors. 
4.4. Functional Analysis of Novel Candidate Genes  
 
To establish the validity of our significant gene deletions, we searched for genomic assays 
that corroborated our findings and identified plausible biological mechanisms in which the genes 
could have affected drug-related phenotypes. To accomplish this, we performed a functional 
analysis of all our significant genes using GeneWeaver.70 There, we performed a systematic search 
of the genes which altered 2BC phenotypes to determine whether they were represented in 
previous curated genomic data sets from studies of humans, mice, and rats. Among the data 
resources used in the analysis were the following: Medical Subject Headings (MeSH)97 related to 
drugs or addiction, Gene Ontoloy (GO)98,99 terms related to drugs or addiction, Quantitative Trait 
Loci (QTL)100 genesets related to drugs or addiction, Kyoto Encyclopedia of Genes and Genomes 
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(KEGG)101–103 pathways related to addiction and alcoholism, Neuroinformatics Framework Drug 
Related Genes (DRG)104, and Genomewide Association Studies (GWAS)105 of alcohol and 
substance use related traits (Sup Table 5).  
All fifteen of the genes were supported by additional evidence from at least one of the searched 
databases establishing prior connections to drug related studies, either through expression data, 
QTL mapping, or connections to drug related biological mechanisms. For example, Hdac10 is part 
of the curated KEGG pathway for alcoholism in humans (hsa05034), mice (mmu05034), and rats 
(rno05034); it is also shown to be upregulated in the nucleus accumbens of cocaine-treated mice 
relative to their saline controls (GS87011).106 In addition to the functional analysis of drug related 
gene sets in GeneWeaver, our bioinformatics approach also assessed our significant genes for 
overlap in biological pathways. Using Gene Set Enrichment Analysis (GSEA)107,108 a systematic 
search of Canonical, KEGG, GO biological or cellular pathways revealed none of our genes were 
annotated to the same pathways. (Accession date 02/04/2020). These results suggest that these 
single gene knockouts may all alter drug-related phenotypes through multiple independent 
biological pathways and mechanisms.  
4.5. Heterogeneous Behavioral Profiles Underlying Drug-Related Phenotypes  
 
Results from our initial screening corroborate those from previous studies which found shared 
genetic components underlying predisposing and subsequently drug-related phenotypes.2,3 These 
shared genetic components led others to find predictive relationships between the drug-naïve 
behaviors of inbred mice and their drug-related phenotypes. 54–57 To build upon these studies, we 
looked to further examine these relationships in a multidimensional manner using the drug-naïve 
and drug-related phenotypes. This analysis was done by preforming a principal component 
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analysis (PCA)109 of effect sizes on all drug-naïve and drug-related traits using the data from the 
sixteen strains tested on phenotypes and all three drugs (Fig 3). Results from the analysis indicates 
that principal component 1 (PC1) explains 21.1% of the variance in these traits and separates the 
mice that have ethanol preference and consumption phenotypes from those that do not. The second 
principal component (PC2) explains 17.8% of the variance and can be used to separate the different 
baseline behavioral profiles that underlie the ethanol-preferring strains, namely, low anxiety/high 
risk taking strains from the high exploration/ high activity strains (e.g., center permanence time 
and total number of rears in open field respectively).  
Examining the results from the PCA, strains with significant drug-seeking phenotypes can 
be found in all four quadrants of the graph, each representing a different baseline behavioral profile 
predictive of different drug related phenotypes. Two ethanol preferring strains that exemplify 
different baseline behavioral profiles are Il12rb2 (found among strains with risk taking/low 
avoidance behaviors) and Hspb2 (found among strains with high exploratory behaviors). Although 
both of these knockout strains showed an ethanol-preferring phenotype, the different behavioral 
profiles segregated along PC2, which also correlated with MA consumption phenotype. The 2BC 
choice data reveals that Il12rb2 knockout mice have a significant MA consumption phenotype 
whereas Hspb2 knockouts do not. Thus, results from the principal component analysis show the 
diverse multidimensional nature of the relations underlying the many predisposing behaviors and 
their predicted drug-related phenotypes. Rather than reflecting a uniform predictive relationship 
between each behavioral phenotype and its predisposing effect on drug intake, 50,82–84 these 
findings indicate a complex interaction of all the predisposing behaviors and their effects on drug-
related phenotypes across different drugs, and that many biological mechanisms support the 
distinct relations among baseline behaviors and drug-related phenotypes.  
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Through deeper exploration of these relationships, one can gain a better understanding of 
the specific relationships among biological pathways and behavioral processes that lead to 
heterogeneous behavioral and genetic mechanisms of addiction and substance use. Relationships 
resulting in apparently similar on drug self-administration in particular individuals would be 
difficult to discern from GWAS where a uniform population-wide relationship between genetic 
variants and addiction risk traits is assumed.  
4.6. Multidimensional Assessment of Predisposing Behaviors  
 
In order to reflect the complex multidimensional relations underlying drug-related phenotypes 
and their predisposing drug-naïve phenotypes we used a multidimensional measure of 
phenodeviance to identify our next round of candidate genes for screening. To assess the 402 
strains tested in the KOMP2 pipeline for overall phenodeviance we performed a Mahalanobis 
calculation for all strains compared to the C57BL/6NJ control using drug-naïve behavioral traits 
from the open field, light dark, holeboard, and acoustic startle tests.  
Using traits from these four behavioral tests, we identified one hundred twenty-three strains 
which displayed overall significantly phenodeviant behavior from the control strain. Of the one 
hundred twenty-three phenodeviant strains, we prioritized the rederivation of the most extreme 
strains. Using findings from the initial screen we hypothesized that the mice that showed the 
greatest overall phenodeviance would manifest multi-drug phenotypes at a higher rate since where 
were combining all predisposing behaviors into a single predictive value. 
Due to availability of sperm, success of in vitro fertilization, and viability of the lines for 
producing viable cohorts, we were able to test thirteen of the most extreme phenodeviant strains. 
These strains were rederived and tested solely due to the Mahalanobis score ranging from 517-
1983(Fig. 4) and had no prior evidence suggesting they may alter drug-related phenotypes. In 
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addition to the thirteen strains chosen solely for their Mahalanobis score, two other expert 
nominated KOMP lines were chosen for testing. These two strains, Rap2b and Tmod2, were among 
the one hundred twenty-three strains found to be significantly deviant, but were found to be on the 
moderate to lower end of phenodeviance spectrum (288 and 115 respectively). Finally, along with 
the KOMP single gene knockout lines, six other expert nominated strains were chosen for testing.  
While in the initial screening we were limited to strains which were alive and available at the 
time of testing, our second screening allowed for the rederivation of the most overall phenodeviant 
strains based on their Mahalanobis score. We hypothesized that rederivation of the strains which 
were the most overall deviant across all predisposing traits would enrich our ability to detect more 
genes that underlie drug-related phenotypes and identify more candidate genes which have multi-
drug effects.  
4.7. Refining Assessment of Drug-Related Phenotypes  
 
To assess the chosen strains for significantly altered patterns of drug-related phenotypes, we 
used the same MA 2BC protocol and updated our EtOH protocol to a more translationally relevant 
binge drinking DID paradigm.79 This protocol is a limited access protocol which has been refined 
to induce mice to drink to levels of intoxication (~100 mg/dL), where they would not normally in 
a 2BC protocol since EtOH is only moderately rewarding.76 This protocol allows for similar overall 
consumption measures (mg/kg) of EtOH across the four days of limited exposure, measurement 
of binge drinking phenotypes, and potential difference in EtOH sensitivity which could affect 
pleasurable and rewarding responses to drug use. As previously stated, there is a significant 
comorbidity of alcohol and MA use37,110 but newer evidence suggests that binge drinking has a 
significantly higher comorbidity rate and is a better predictor for MA use than moderate drinking. 
37,110,111 Using these two protocols were able to screen our extreme single gene knockout strains 
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for drug-specific effects and also strong multi-drug effects that alter drug-related phenotypes 
across drugs, testing procedures, and have strong translational relevance to human patterns of MA 
and alcohol use.  
4.8. Improved Identification of Genes Altering Methamphetamine Use 
 
Using a multidimensional analysis to identify extreme overall phenodeviant strains greatly 
increased our ability to identify strains which had significantly altered patterns of MA use. Of the 
fifteen strains chosen for their Mahalanobis score, 12 showed significant differences on one of our 
three measured drug-related phenotypes, and eight directly altered MA use. The use of 
Mahalanobis distance to identify strains with predisposing behaviors increased our ability to 
identify genes which affect methamphetamine use by ~ 36% from a 17.6% (3/17) success rate to 
53.3% (8/15). A success rate of 53% for identifying genes that altered MA-related phenotypes 
from only predisposing drug-naïve behaviors, while not as high a rate as expert nominated strain 
80% (4/5), is a notable accomplishment.  
 In our MA 2BC we observed no main effect of sex across any measure of MA-related 
phenotypes which corroborates previous MA studies that also detected no significant interactions 
of sex91,92. Six of our fifteen phenodeviant knockouts resulted in a main effect of strain which 
increased general preference for MA compared to controls. (Fig 5A) Three of these six strains 
which showed increased preference for MA also had a significant main effect of strain, which 
significantly increased their consumption of MA (mg/kg). (Fig 5b)  
Five of the screened knockout strains resulted in significant strain × dose interactions. For the 
control strains and the knockouts, preference for MA trended down as doses increased, with the 
initial dose of 10 mg/L being their most preferred dose. Control strain had an average initial 
preference for MA 31.5%±3.3, and most significant knockouts had initial preferences ranging from 
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41.5%-57.8%. Myh10, Dnaja4, Tmod2, and Rap2b knockouts resulted in a shift in their dose 
response curves and had the highest average preference for the 20 mg/L dose 48.0% and 47.4% 
respectively. (Sup Panel 6) Other significant strain × dose interactions revealed increased 
sensitivity to increasing dosages on MA. While Dnmt3a, Cp, and Lrrc15 displayed initially 
increased preference for MA at the initial dose compared to control, they all also showed decreased 
preference to MA at higher doses, specifically at the 40 mg/L dose. These results show that the 
multidimensional approach to identifying phenodeviant strains greatly enriched our ability to 
detect gene which had an effect on MA compared to the initial screen.  
All of our expert nominated strains were previously identified based on human or model 
organism stimulant studies. Of the two expert nominated C57BL/6NJ strains, only Trib3 resulted 
in any significant alterations of MA use. C57BL/6J derived strain, Bmerb1 displayed significantly 
increased MA consumption at the highest dose compared to controls. This suggests that deletion 
of this gene may potentially lead to reduced efficacy of MA resulting in increased consumption at 
higher doses that are aversive to their control strain. In comparison to these results, deletion of the 
Bmerb1 gene in the C57BL/6J strain resulted in increased preference and consumption and the 40 
mg/L dose and decreased both at the 80/ mg/L dose compared to controls. Deletion of Bmerb1 
resulted in the only significant effect of sex for all MA phenotypes. Differences in preference and 
consumption at 40 mg/L were driven by the males who displayed increased preference and 
consumption compared to females and controls. Finally, while Bmerb1 preference and 
consumption of MA equal to or greater than controls at the first three doses, the KOs displayed 
increased aversion to the final 80 mg/L dose. This finding suggests that Bmerb1 may a role 




The expert nominated strains of particular interest in our MA 2BC paradigm are the 
C57BL/6J-Taar1(D2KI) and DBA/2J-Taar1(B6KI) strains with the allele swap. The trace amine-
associated receptor 1 (Taar1) gene was identified as a potentially important gene involved in MA 
intake in a quantitative trait loci (QTL) mapping study using MA high drinking (MAHDR) and 
low drinking (MALDR) strains from the BXD RI panel.112 In this study Phillips and colleagues 
identified a QTL on chromosome 10 that accounted for 50-60% of genetic variance of MA 
intake.91,112 In the initial study using MAHDR and MALDR, it was found that the MAHDR 
phenotype segregated with the non-functional version of the Taar1 gene, making it a risk factor 
MA use.112 Further examining the BXD RI lines and their history, it was found that BXD lines 
which were older and derived earlier in BXD projects only had B6 functional versions of the Taar1 
gene, but some of the newer derived strains made using DBA/2J as their progenitors had the non-
functional of the gene.92,113 This finding led to the sequencing of the non-functional Taar1 gene to 
find a single nucleotide polymorphism (SNP) at position two hundred twenty-nine. At position 
two hundred twenty-nine a cytosine is altered to an adenosine, which results in a missense mutation 
changing a non-polar Proline to a polar Threonine.113,114 This missense mutation occurs in Taar1’s 
only exon and inhibits proper folding in Taar1’s transmembrane domain, leading to a lack of 
function. 113,114 
To validate that this exact SNP is responsible for the increased MA intake observed in the 
DBA/2J and the BXD lines which inherited its Taar1 allele, we performed a gene swap with 
C57BL/6J. In our gene-swap KI strains, we recreated the SNP at position two hundred twenty-
nine in codon seventy-seven. This changes a Proline to a Threonine in our C57BL/6J line 




Results from our screening using a 24-hour access 2BC protocol (Fig 5C-F) validate that this 
SNP is responsible for the observed increased MA intake, and restoration of its function can 
alleviate risk factors for MA use. This mutation was originally discovered using a limited access 
2BC paradigm which was necessary for high levels of MA intake. While our DBA/2J and 
C57BL/6J-Taar1(D2KI) strains did not consume to the excess that the MAHDR strains did in the 
limited access paradigms, it speaks to the strength of the phenotype observed with the Taar1 
mutation. Our results show that the mutation still has significant effects and increases consumption 
when MA is available ad libitum, and it can be parsed out from the limited access paradigm which 
drives increased MA consumption. Validation of this SNP as the causal variant leading to 
increased MA consumption provides a strong potential target out of the two hundred variants 
observed in TAAR1.115 Further research of this variant could lead to potential treatments for MA 
use in humans through TAAR1 agonists in addition to serving as potential screening marker for 
assessing vulnerability to MA use in humans.  
4.9. Strains Assessed for Ethanol Related Phenotypes Using DID Protocol 
 
In our second screening we augmented our protocol for EtOH drinking from an ad libitum 
2BC protocol to a limited access DID protocol, with the hopes of identifying genes which 
significantly affected the more translationally relevant binge drinking phenotype. It has been 
shown that EtOH consumption is only moderately rewarding76 from a physiological standpoint in 
mice. Throughout the course of the ad libitum 2BC protocol BEC changes rapidly, and mice do 
not sustain pharmacologically relevant levels of BEC.116 Although preference drinking is a widely 
used and valid partial model for alcohol use117,118, we felt using the DID protocol to measure 




Findings from our project corroborate those of previous studies on EtOH binge-like 
experiments, which found that female mice consume higher levels of EtOH than male mice.119–121 
Another closely related study hypothesized that this may be due to an inherently heightened risk 
for excessive EtOH consumption in females related to the drugs ability to reduce a naturally more 
active stress response 122. In our study, we found that for every strain tested there was a significant 
main effect of sex, and females drank more than males when corrected for body weight (mg/kg) 
in every case (Sup Panel 7).  
Using the DID protocol, we found that four of fifteen phenodeviant strains had significant 
EtOH phenotypes. All four gene deletions altered EtOH consumption over the four days of limited 
access. Irf8 and Elof1 strains both displayed reduced EtOH consumption for both male and females 
compared to control strain. Tmod2 and Zbtb4 both had significant strain × sex interactions as 
indicated by decreased consumption for the female lines but no difference in male consumption 
compared to controls. This suggests that unlike deletion of the Irf8 gene, which has the same effect 
on both sexes across both drugs, deletion of these three genes results in sex differences in EtOH 
consumption.  
We found that our measure of EtOH intake is a moderately strong predictor of BEC with an 
r2 = 0.49 across all twenty strains and both sexes. This correlation for consumption on day four 
and the resulting BEC is comparable to one found in the creation of the DID protocol which was 
r2 = 0.53 using only female C57BL/6J from different sites or r2 = 0.50 when using both males and 
females.77 This indicates our measures of BEC are reliable even with our altered process of blood 
collection based on refinement of the protocol in Thiele et al. 2016.  
The findings of sex differences in responses of Tmod2 and Zbtb4 to EtOH are particularly 
interesting because they both also significantly altered MA intake but no effect of sex or strain × 
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sex was detected. The sex differences in Tmod2 phenotypes corroborate findings from previous 
studies done using BXD RI lines which found sex differences in gene expression in various 
locations throughout the reward pathway following drug exposure.55 Through a functional analysis 
of all our significant genes, it was found that the gene sets from this study included Tmod2 as a 
gene which was differentially expressed following drug exposure in a sex dependent manner. 
These data indicate deletion of Zbtb4 and Tmod2 may alter the response of the reward pathway in 
a drug by sex specific manner.  
Of the fifteen phenodeviant strains chosen for screening in the DID paradigm, none of the strains 
resulted in a significant BEC phenotype following multiple testing corrections. This may in part 
be due their C57BL/6NJ background which was found to have low BEC levels in our experiment. 
An important finding in this study was the differences observed between the control C57BL/6J 
and C57BL/6NJ control strains. As previously stated, this protocol was developed to induce 
pharmacologically relevant BEC levels in C57BL/6J strains. Our results indicate that this was true 
for all our C57BL/6J derived strains but was unsuccessful for all of our C57BL/6NJ strains. In our 
experiment, C57BL/6J mice consumed on average 13% more ethanol than C57BL/6NJ mice, 6% 
and 30% for females and male respectively, on the final day of the DID protocol. While C57BL/6J 
mice only drank on average 13% more across both sexes than the C57BL/6NJ mice, this resulted 
in a 113% increase in BEC levels. This is suggestive of potential differences in EtOH metabolism 
between the two control strains. While only drinking slightly less than their C57BL/6J 
counterparts, C57BL/6NJ mice did not reach pharmacologically relevant levels of BEC, possibly 
due to increased rate of EtOH metabolism. These decreased consumption and BEC levels were 
consistent across all C57BL6/NJ-derived lines. This increased metabolism could have contributed 
to the decreased number of significant strain effects we were able to detect due to a floor effect. 
59 
 
Since our control strain started with a lower average BEC and most deletions either did not alter 
BEC or tended to decrease BEC levels further, this protocol was less suited to detecting strain 
effects in the C57BL/6NJ lines.  
Nr2f1 was the only expert nominated strain to result in a significant effect of strain for both EtOH 
consumption and Average BEC measurements. Deletion of the Nr2f1 gene significantly lowered 
EtOH consumption across both sexes and consequently was the only gene which significantly 
altered average BEC for both sexes. Deletion of Nr2f1 resulted in a decreased consumption on day 
four from control levels of 9.03 ± 0.44 mg/kg and 3.73 ± .45 mg/kg for females and males 
respectively to 6.21 ± 0.42 mg/kg and 1.05 ± .38 mg/kg respectively. This resulted in a decrease 
of average BEC from control levels of 76.8 ± 18.1 mg/dL and 25.2 ± 6.0 mg/dL for females and 
males respectively to 42.45 ± 15.0 mg/dL and 1.69 ± .64 mg/dL respectively. Nr2f1 has previously 
been connected to optic atrophy and intellectual disability123, it has also been found to be one of 
475 genes which were differentially expressed in the striatum of C57BL/6J mice following 
drinking to intoxication in a DID paradigm.124 This suggests that the decreased consumption and 
corresponding BEC may not be due to vision or intellectual problems, but deletion of the Nr2f1 
gene may alter response to EtOH in the reward pathway.  
While females from only two C57BL/6NJ strains (Lrrc15 and Trib3) reached binge 
drinking levels with average BECs above 100 mg/dL, the results from our DID screening are still 
important for examining the role our candidate genes play in EtOH drinking and susceptibility.  
4.10. Identification of Phenodeviant Strains Using Multidimensional Analysis 
Improved our Ability to Identify Genes with Multi-Drug Effects 
 
In our second screening, of the fifteen strains which were selected for being extremely 
phenodeviant, ten strains resulted in significantly altered patterns of drug-related phenotypes. 
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Three of our KO strains resulted in significant effects on both MA and EtOH phenotypes. While 
the total percentage of genes we tested that resulted in at least one significant effect was not as 
high as our original screening (79%, 15/19), we greatly increased our ability to identify genes 
which effected MA to 53.3% (8/15) from ~18% (3/17). Importantly, we also increased our ability 
to identify genes which had multi-drug effects on both MA and EtOH from 12.5% (2/16) to 20% 
(3/15). Reduced number of strains which had significant EtOH phenotypes is presumably due to 
the refined EtOH protocol used in the second screening with a more translationally relevant binge-
like phenotype. Overall, the use of a multidimensional assessment of predisposing behaviors 
improved our identification of gene KOs which altered MA-related phenotypes in addition to 
improving our ability to identify genes such as Irf8, Tmod2, and Zbtb4 which significantly altered 
phenotypes on multiple drugs. 
4.11. Conclusions and Future Directions 
 
Overall, our data indicates the utility of leveraging the known complex relationships among 
predisposing drug-naïve behaviors and addiction risk phenotypes. In this project, we used and 
refined our understanding of these relationships in combination with the high-throughput JAX-
KOMP2 program to identify thirty-three plausible single gene KO strains predictive of addiction 
risk phenotypes. Of those thirty-three plausible candidates, twenty-five gene KOs significantly 
altered drug-related phenotypes. Following screening for drug-related phenotypes, all significant 
genes were validated through functional analysis for having plausible connections and mechanisms 
to affect drug-related phenotypes. Further analysis through GSEA indicated no overlapping 
pathways among our candidate genes that could have possibly affected drug-related phenotypes. 
This indicates that these genes could represent multiple diverse pathways for roles in addiction 
risk. This strategy was therefore successful and circumvented the effects of drug exposure on 
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subsequent physiological testing in the screening program; that is, it allowed us to discriminate 
risk from consequences of drug exposure. An approach that uses a drug-naïve screen is efficient, 
but it will necessarily miss those genes with addiction risk effects that are not manifested in 
predisposing behaviors. Nevertheless, through this study combining publicly available data, 
multiple novel candidate genes, high through-put testing using multiple drugs, and functional 
analysis of multiple genomic databases, we have now identified twenty-five new addiction risk 
genes amenable for detailed characterization in viable mutant mice.  
While addiction risk genes are often independent from the genes predisposing for transition 
from initial use to addiction, further characterization of these genes and associated pathways could 
elucidate their or related pathway gene’s distinct roles in the process of transition addiction. Our 
findings suggest that the continued phenotyping of inbred single gene knockout mice using the 
broad neurobehavioral screen from KOMP will allow for the continued identification on novel 
addiction risk genes. Through our particular project we were able to detect multiple genes affecting 
drug using through a diverse set of biological pathways. Each of these genes would only accounts 
for small proportions of the genetic variation and would often be missed using GWA studies. 
Hopefully moving forward, building off the findings from this study, the continual screening of 
KO mice for predisposing drug-naïve behaviors can lead to further discovery of more novel 
addiction risk genes that would not be discovered easily using hypothesis-driven or other discovery 
based techniques. This continual identification and characterization of novel addiction risk genes 
will hopefully lead to better screening for vulnerability to SUDs and addictions as well as potential 
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